Revenue Growth
Revenue for the quarter was $3.3 billion, an increase of 10% compared to the fourth quarter of 2023. Diagnostics and biopharma revenue each grew by approximately 10% in the quarter.
Acquisitions and Strategic Collaborations
Completed acquisitions of select assets and molecular testing locations of Lab Works and select outreach laboratory services for Ballad Health. Announced a strategic collaboration with Inspira Health.
Adjusted EPS Increase
Adjusted EPS of $3.45 was up 5% year-over-year.
Strong Free Cash Flow
Free cash flow from continuing operations was $665 million for the quarter.
Launch of New Diagnostic Tests
Introduced new diagnostics, including a multiple sclerosis monitoring profile and the first companion diagnostic assay to identify gastric cancer patients eligible for targeted treatment.
Expansion in Genetic Testing
Expanded leadership in genetic testing solutions through the acquisition of select assets of Invitae.
Promising 2025 Guidance
Expecting enterprise revenue growth of 6.7% to 8% and improving margins across both diagnostics and biopharma. Anticipated adjusted EPS range of $15.60 to $16.40, representing a midpoint growth rate of 10%.